Screener
Xeris Biopharma Holdings, Inc. XERS Recorlev — Product revenue, net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001867096-26-000065
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Product revenue: | ||||
| Recorlev | $56,780 | $31,444 | $106,548 | $56,974 |
| Gvoke | 22,549 | 23,467 | 43,349 | 44,312 |
| Keveyis | 11,675 | 11,485 | 23,561 | 22,912 |
| Other product revenue | — | 1,312 | — | 1,312 |
| Product revenue, net | 91,004 | 67,708 | 173,458 | 125,510 |
| Royalty, contract and other revenue | 1,096 | 3,831 | 1,769 | 6,148 |
| Total revenue | $92,100 | $71,539 | $175,227 | $131,658 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Xeris Biopharma Holdings, Inc.'s recorlev — product revenue, net?
- Xeris Biopharma Holdings, Inc. (XERS) reported recorlev — product revenue, net of $56.78M in Q2 2026.
- How has Xeris Biopharma Holdings, Inc.'s recorlev — product revenue, net changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s recorlev — product revenue, net increased by 80.6% year-over-year, from $31.44M to $56.78M.
- What does recorlev — product revenue, net mean?
- This metric represents the total net sales generated from the commercialization of a specific pharmaceutical product after accounting for returns, rebates, and other sales deductions. It serves as a primary indicator of the product's market adoption, commercial traction, and contribution to the company's overall top-line growth within its therapeutic focus area. Tracking this figure allows investors to evaluate the success of the product's launch trajectory and its ability to capture market share in its respective indication.
Ask your AI about Xeris Biopharma Holdings, Inc.'s recorlev — product revenue, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude